Therapy News and Research

RSS

Later-life estrogen therapy associated with lower risk of developing dementia

Use of hormone therapy later in life was associated with lower risk of developing dementia, according to a study published August 12, 2026, in Neurology, the medical journal of the American Academy of Neurology.

12 Aug 2026

Personalized T-cell therapy eliminates advanced kidney tumor in teenager

Researchers and physicians at the Hopp Children's Cancer Center Heidelberg (KiTZ) and other leading cancer centers report an exceptional treatment success in an adolescent with an advanced, therapy-resistant kidney tumor.

12 Aug 2026

Intensive blood pressure control lowers stroke recurrence risk in ICH survivors

Intensive, long-term blood pressure-lowering treatment reduced the risk of recurrent stroke by 38%, without increasing serious adverse events, in people who have survived an intracerebral hemorrhage (ICH).

12 Aug 2026

AI-based methods help uncover hidden roots of tumor metastasis

A cancerous tumor is not a single enemy. It is made up of many different cell populations that can behave in very different ways.

12 Aug 2026

Mitochondrial gene RTN4IP1 drives triple-negative breast cancer metastasis

Triple-negative breast cancer accounts for approximately 15% of all breast cancer cases. It is characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression, rendering it insensitive to conventional endocrine and targeted therapies.

12 Aug 2026

Researchers find unexpected protein regulator of leukemia drug sensitivity

How cells respond to the leukemia drug 6-thioguanine still holds surprises: A new study, led by researchers from CeMM and the University of Oxford identifies NUDT5 as an unexpected regulator of drug sensitivity and reveals that its role has nothing to do with its enzymatic activity.

12 Aug 2026

Targeting single gene reverses developmental deficits in adult mice

Some of the symptoms of neurodevelopmental disorders (NDDs) such as autism spectrum disorder and epilepsy may result from dysfunction of certain neurons in the brain and their ability to change their properties in response to experiences-a process called experience-dependent plasticity.

12 Aug 2026

Insilico Medicine nominates powerful oral drug candidate for the management of heart risks

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM0900, a potent, AI-driven, highly selective, orally available small molecule inhibitor of lipoprotein(a), or Lp(a), as a preclinical candidate (PCC) for the management of cardiovascular risks.

12 Aug 2026

Molecular mapping reveals hidden cellular programs in heart transplant rejection

A new study that explores gene expression during heart transplant rejection marks a step forward for precision medicine approaches to treat organ rejection.

12 Aug 2026

Cannabis compounds may weaken glioblastoma response to chemotherapy and radiation

Several cannabinoids reduced chemotherapy- and radiation-induced apoptosis in glioblastoma cell models, with effects linked to reduced apoptotic priming, increased pro-survival signaling, and G1 cell-cycle arrest. The findings raise concern that cannabinoid exposure could interfere with some cancer treatments, although the results are limited to laboratory models and require in vivo and clinical validation.

12 Aug 2026

Genetic tool turns soft cancer cells into immune targets

Researchers at the USC Viterbi School of Engineering and Keck School of Medicine of USC have engineered a remarkable genetic tool that addresses one of the most persistent obstacles in cancer immunotherapy: the physical softness of tumors.

11 Aug 2026

Microcurrent stimulation shows immediate reduction in surgical scar depth

A newly accepted pilot study in the Journal of Bodywork & Movement Therapies reports that direct-current (DC) microcurrent stimulation was associated with a statistically significant reduction in measured postsurgical scar depth immediately following a single treatment.

11 Aug 2026

Huge philanthropic grant funds pioneering stem cell-based heart attack therapy

In a landmark moment for both the treatment of heart disease and philanthropic support, The Marcus Foundation has awarded the head of USC Stem Cell Center, Chuck Murry, MD, PhD, $28.7 million to advance a clinical trial testing a stem cell-based therapy designed to regenerate damaged tissue after a heart attack.

11 Aug 2026

Dexamethasone calms lung inflammation without weakening core immune responses

Researchers from Trinity College Dublin and St. James's Hospital have shown that dexamethasone, a commonly prescribed anti-inflammatory steroid, can reduce harmful inflammation triggered by Mycobacterium avium without weakening the ability of human immune cells to control the infection.

11 Aug 2026

HonorHealth begins trial of dendritic cell vaccine for advanced melanoma

Physicians at HonorHealth Research Institute have begun a clinical trial of a new, potentially more powerful, treatment for fighting advanced melanoma, using the immune system's dendritic cells to create a vaccine.

11 Aug 2026

New study identifies key pathway for delivering antisense cancer drugs

Antisense oligonucleotides (ASOs) have been proposed as a therapeutic approach to shut down the production of faulty proteins in a wide variety of diseases, including cancer.

11 Aug 2026

$Bone loss alone fails to explain diabetes-related fracture risk$

Bone loss alone fails to explain diabetes-related fracture risk

A new study published in Diabetes Care finds that bone loss alone does not explain the increased fracture risk observed in some older adults with type 2 diabetes.

11 Aug 2026

Lab-grown mini tumors help scientists predict breast cancer treatment success

Researchers at UC San Francisco have developed a new method to predict how different types of breast cancer will respond to treatment, using patient data from the I-SPY2 breast cancer trial and rapid testing on lab-grown mini tumors.

11 Aug 2026

New review urges proteostatic fitness standards for stem cell therapies

Stem cell therapies have expanded rapidly, with more than 115 clinical trials involving over 1,200 patients approved by late 2024. The U.S. Food and Drug Administration (FDA) recently approved Ryoncil (remestemcel‑L) for children with steroid‑refractory acute graft‑versus‑host disease, signaling a major shift toward routine clinical use.

11 Aug 2026

Bright-light therapy may reduce attention lapses during night work

Light therapy may improve alertness and attention/reaction time during simulated night shifts, with the strongest benefits appearing after light exposure. Effects on executive function were smaller and largely limited to treatment, while substantial study heterogeneity and limited real-world evidence warrant caution.

11 Aug 2026